(Q45980134)

18 December 2017

title

Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms. (English)

1 reference

18 December 2017

author name string

Ismail Ozdemir

1

1 reference

18 December 2017

Ozan Bozkurt

2

1 reference

18 December 2017

Omer Demir

3

1 reference

18 December 2017

Guven Aslan

4

1 reference

18 December 2017

Adil A Esen

5

1 reference

18 December 2017

language of work or name

English

0 references

publication date

7 June 2009

1 reference

18 December 2017

published in

Urology

1 reference

18 December 2017

volume

74

1 reference

18 December 2017

issue

2

1 reference

18 December 2017

page(s)

431-435

1 reference

18 December 2017

High prevalence of benign prostatic hypertrophy in the community

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.088

EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.088

Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.088

Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.088

Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.088

Cyclooxygenase-2 and prostate carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.088

The effect of partial outlet obstruction on prostaglandin generation in the rabbit urinary bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.088

A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.088

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.088

Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.088

Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.088

Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.088

Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.088

Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.088

Asymptomatic inflammation and/or infection in benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.088

LUTS treatment: future treatment options

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.088

Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.088

Effect of cyclooxygenase inhibitors on the micturition reflex in rats: correlation with inhibition of cyclooxygenase isozymes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.088

A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.088

Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.088

10.1016/J.UROLOGY.2009.01.088

7 January 2021

Identifiers

DOI

1 reference

18 December 2017

1 reference

18 December 2017